Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine
Journal of Clinical Medicine · 25.06.2026 · 15 (13) · 4963
DOI: 10.3390/jcm15134963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.06.2026. Verfasst von Chun-Fu Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Taipei Medical University Hospital, Taipei Medical University, Taipei 110301, Taiwan. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
OnabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies are widely used for chronic migraine prevention, but comparative real-world evidence on healthcare utilization remains limited. This study aimed to compare the association of onabotulinumtoxinA versus CGRP monoclonal antibodies with acute triptan prescription and migraine-related return visits in patients with chronic migraine.
Methods
We conducted a retrospective cohort study using the TriNetX global federated electronic health record database from 2018 to 2024. Adults with chronic migraine who initiated onabotulinumtoxinA or a CGRP monoclonal antibody were matched 1:1 by propensity score. The primary outcomes were time to acute triptan prescription and time to first migraine-related return visit during follow-up.
Results
After propensity score matching, 10,140 patients were included in each treatment group. OnabotulinumtoxinA was associated with a lower hazard of acute triptan prescription than CGRP monoclonal antibodies (hazard ratio 0.513, 95% confidence interval 0.481–0.546; p < 0.001), whereas migraine-related return visits were similar between groups (hazard ratio 1.008, 95% confidence interval 0.977–1.039; p = 0.69).
Conclusions
In this multicenter real-world analysis, onabotulinumtoxinA was associated with a lower hazard of acute triptan prescription than CGRP monoclonal antibodies, while migraine-related return visits were comparable. These findings reflect treatment-related healthcare utilization patterns in routine practice and should be interpreted considering the limitations of retrospective electronic health record data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Taipei Medical University Hospital, Taipei Medical University, Taipei 110301, Taiwan.
- Dizziness and Balance Disorder Center, Taipei Medical University Hospital, Taipei Medical University, New Taipei City 235061, Taiwan.
- Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan.
- Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, Taiwan.
- Department of Neurology, Neurological Institute and Stroke Center, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
ORCID-Profile: Chun-Fu Lin, Chen-Chih Chung, Chaur-Jong Hu, Tu-Hsueh Yeh
Zitieren
APA
Lin, C. F., Chung, C. C., Chen, J. H., Chi, N. F., Hu, C. J., Huang, H. E., Chen, C. C., Yeh, T. H., Wei, J. C., & Lee, H. H. (2026). Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine. Journal of Clinical Medicine, 15(13), 4963. https://doi.org/10.3390/jcm15134963
Vancouver
Lin CF, Chung CC, Chen JH, Chi NF, Hu CJ, Huang HE, et al. Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine. Journal of Clinical Medicine. 2026;15(13):4963. doi:10.3390/jcm15134963
BibTeX
@article{Lin2026,
author = {Lin, Chun-Fu and Chung, Chen-Chih and Chen, Jia-Hung and Chi, Nai-Fang and Hu, Chaur-Jong and Huang, Hung-En and Chen, Chih-Chung and Yeh, Tu-Hsueh and Wei, James Cheng-Chung and Lee, Hsun-Hua},
title = {Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {4963},
doi = {10.3390/jcm15134963}
}
EUVIMED